News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UV Flu Technologies Inc. Forecasts Record Allergy Season and Revenues



4/4/2013 11:08:58 AM

BARNSTABLE, Mass., April 3, 2013 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCQB: UVFT)(the "Company") announced today that the Company is forecasting that this year may the worst allergy season ever, particularly in the Northeast, as well as many northern states.

"This Winter has conditions in place for a horrible allergy season," said Jack Lennon, President of UV Flu Technologies. "Record snowfalls in many of the 48 states this season that did get snow, not only put in place high levels of moisture, but record levels of nitrogen, which stimulates plant growth in a fertilizer-like fashion. When added to the warmer global temperatures, longer allergy season, and higher CO2 levels, we expect record levels of pollen, mold and mildew, particularly acute in areas that were impacted by Hurricane Sandy," said Mr. Lennon

"We highly recommend a high quality air purifier, like our ViraTech UV-400, to the over 50 million Americans that suffer from allergy and asthma symptoms. Although our device is filter-less, and treats almost all forms of indoor air pollution, including smoke and toxic chemicals, it is very important that users of filter-based technologies change their filters regularly, as the filter mediums can become infected, and actually make allergies worse," said Mr. Lennon.

"Consumers are just beginning to recognize that the purchase of a high quality air purifier may be the most cost-effective purchase they've ever made for the health and safety of their entire family, particularly families with asthma, allergies, or other medical conditions. No one would ever allow their children to drink water they knew to be contaminated, yet the toxic air they breathe daily in their home is left untreated. Ninety-eight percent of consumers that purchase our ViraTech UV-400 air purifier report dramatically reduced levels of allergy symptoms, along with better sleep at night."

"Our 1st quarter sales increased 75%, but we expect growth rates two to three times this rate for the second and third quarter of this year. With this in mind, we are adding Mr. Glenn Bushee, President of Brite-Strike Technologies, to our Board of Directors. Mr. Bushee's extensive experience in marketing and production will be of immense value to our Company," said Mr. Lennon.

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the ViraTech UV-400.

About UV Flu Technologies, Inc. (OTCQB: UVFT)
UV Flu Technologies is an innovative developer; manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO

Investor Information:
Toll-Free: 1-877-358-5545 (FLU-KILL)
Web: www.uvflutech.com

Retail or Internet Inquires:
Please call our Corporate Office at: 508-362-5455

SOURCE UV Flu Technologies, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES